FDA Accepts Supplemental NDA for Subvenite (Lamotrigine) by OWP Pharms
The FDA has accepted a supplemental NDA for Subvenite, which contains lamotrigine as the active ingredient.
Asset / Drug
Drug and asset intelligence for Subvenite with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.